Steve Hahn

Steve Hahn is a prominent healthcare executive and former government official with extensive experience in oncology and medical research. He currently serves as the CEO of Harbinger Health and CEO-Partner at Flagship Pioneering.34

Professional Background

Dr. Hahn has had a distinguished career spanning various leadership roles:

• Current Positions: CEO of Harbinger Health and CEO-Partner at Flagship Pioneering since December 2021.3
• Government Service: Served as the 24th Commissioner of the U.S. Food and Drug Administration (FDA) from December 2019 to January 2021.12
• Academic Medicine: Prior to his FDA role, he held several high-ranking positions at MD Anderson Cancer Center, including Chief Medical Executive and Deputy President/Chief Operating Officer.12
• Research and Clinical Practice: Focused on radiation oncology, with leadership roles at the University of Pennsylvania's Perelman School of Medicine.12

Education and Training

Dr. Hahn's educational background includes:

• M.D. from Temple University School of Medicine.13
• B.A. in Biology from Rice University.13
• Residency in internal medicine at the University of California San Francisco.12
• Fellowship and residency at the National Cancer Institute in Bethesda, Maryland.12

Current Focus

At Harbinger Health, Dr. Hahn is working on pioneering the detection of early cancer through blood-based tests.4 The company aims to develop affordable and accessible early-stage cancer screening methods.5

Research and Publications

Throughout his career, Dr. Hahn has made significant contributions to medical research:

• Authored over 220 peer-reviewed original research articles.12
• Focused on tumor microenvironment, signal transduction pathways, and proton therapy.12

Dr. Hahn's diverse experience in healthcare leadership, oncology, and regulatory affairs has positioned him as a key figure in the development of innovative health technologies and cancer detection methods.